---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093326"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:44:19.317569+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement

## Summary
- Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
- Placed 17 ALLY Systems in Q2 2024, highest since launch; total installed base ~330 systems.
- Worldwide procedure volume increased 19% to 42,203 in Q2 2024 from 35,349 in Q2 2023.
- Terminated Development Agreement with Oertli Instrumente AG effective Aug 5, 2024, with no termination penalties.
- Received MDR certification (CE Mark) and Taiwan FDA approval; first EU and SE Asia ALLY systems shipped.

## SEC filing metadata
- accession: 0000950170-24-093326
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000095017024093326/0000950170-24-093326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000095017024093326/lnsr-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093326
- JSON: https://secwatch.observer/filing/0000950170-24-093326.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.